Cala Health, Inc., a Burlingame, Calif.-based bioelectronic medicine company developing wearable therapies for chronic disease, completed a $50m Series C financing.
New investors included Novartis, Baird Capital, LifeSci Venture Partners, TriVentures, and others. All existing investors participated in the round, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital, and GV.
As part of the financing, industry veteran Stacy Enxing Seng will be joining Cala Health’s team as an Independent Director and Board Chair.
The company intends to use the funds to introduce its Cala TrioTM to the market as well as expand its therapeutic pipeline.
Led by Kate Rosenbluth, PhD, Founder and CEO, Cala Health has developed Cala Trio, a breakthrough therapy for hand tremors in people with essential tremor. The company is preparing for the limited release of the prescription Cala Trio therapy.
Cala Health recently announced completing enrollment in the largest therapeutic study ever conducted in essential tremor in the US, the landmark PROspective study for SymPtomatic relief of Essential tremor with Cala Therapy (PROSPECT). The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health’s wearable therapy is essential tremor.
New therapies are under development in neurology, cardiology, and psychiatry.